HFNC與NIV對I型呼吸衰竭患者的應用價值分析

Application value analysis of HFNCoxygen therapy and NIV in patients with type I respiratory failure

10.12408/J.issn2223-4462.2024.01.016

石漢輝(SEAK Hon Fai)；季銀樑(Kuai Ngan Leong)；陳劍龍(CHAN Kim Long)

I型呼吸衰竭 ； 經鼻高流量氧療 ； 無創通氣 ； Type I respiratory failure ； HFNC ； NIV

鏡湖醫學

24卷1期（2024 / 06 / 01）

49 - 51+41

繁體中文;英文

目的：分析對於I型呼吸衰竭患者採用經鼻高流量氧療（HFNC）氧療對比無創通氣（NIV）治療的應用價值。方法：選取2022年5月～2023年4月在鏡湖醫院急症室使用HFNC及NIV治療的I型呼吸衰竭患者，分析基礎資料、治療結局、呼吸困難評分、舒適度評分。結果：HFNC組41例、NIV組26例。治療後的呼吸困難評分（VAS）、呼吸頻率的差異無統計學意義；治療後的氣合指數（PaO_2/FiO_2）在NIV組改善更多，差異有統計學意義。在急症室通過HFNC或NIV治療2小時內的失敗率、入院後續用HFNC或NIV治療6小時內插管率、28天病死率，差異均無統計學意義。HFNC組舒適度評分更高，差異有統計學意義。結論：對於I型呼吸衰竭患者，HFNC與NIV均可改善Ⅰ型呼吸衰竭患者生理指標及血氣分析指標，但與NIV比較，患者對HFNC的耐受性更好，更利於患者臨床治療。

Objective: To analyze the application value of high-flow nasalcannula (HFNC) oxygen therapy compared with noninvasive ventilation (NIV) in patients with type I respiratory failure. Methods: Patients with type I respiratory failure who were treated with HFNC and NIV in the emergency department of Kiang Wu Hospital from May 2022 to April 2023, were selected to retrospectively analyze basic data, treatment outcomes, dyspnea scores, and comfort scores. Results: There were 41 cases in the HFNC group and 26 cases in the NIV group.There was no statistically significant difference in dyspnea score (VAS), and respiratory rate (RR) after treatment. Oxygenation index (PaO2/FiO2) become better in NIV group more than HFNC group, there was statistically significant difference.The failure rate within 2 hours of treatment with HFNC or NIV in the emergency department, the rate of intubation within 6 hours after admission with HFNC or NIV, 28-day mortality rate, all of that the difference was not statistically significant. The comfort score was better in the HFNC group and the difference was statistically significant. Conclusion: For patients with type I respiratory failure, HFNC is better tolerated than NIV, and that is more conducive to clinical treatment.